The dream of extending human life has occupied scientists, philosophers and ordinary people for centuries. Modern medicine has already made enormous progress in preventing premature death, but the more ambitious goal of reversing biological ageing remains largely beyond our reach. A new study published in Aging Cell in October 2026 provides another intriguing piece of the puzzle. Researchers have demonstrated that human cells obtained from elderly donors, including individuals over 100 years old, can undergo dramatic reductions in molecular markers associated with ageing.
The research, conducted by Lea Jessica Berg and colleagues at the University of Bonn and RWTH Aachen University, examined the conversion of human blood-derived cells into induced neural stem cells. Their findings raise an important question: if scientists can substantially reverse ageing signatures in isolated human cells, might similar principles eventually be employed to repair ageing tissues and extend healthy human life? The answer is potentially yes, but with some substantial qualifications.
The researchers used two transcription factors, SOX2 and cMYC, to reprogramme blood-derived erythroid progenitor cells into induced neural stem cells, or iNSCs. These are cells capable of generating different types of neural cells, making them potentially valuable for studying neurological diseases and developing regenerative treatments.
The remarkable finding concerned the apparent biological age of the resulting cells. Using a DNA methylation-based epigenetic clock, the researchers found that the reprogrammed cells retained approximately 13 per cent of their donors' original epigenetic age at early passages, declining to approximately 5 per cent after further cultivation.
These percentages refer to the age estimates produced by the molecular clock, not to the percentage of physical ageing reversed throughout the donor's body. Nevertheless, the results were striking. Cells originating from very old individuals could acquire molecular characteristics associated with much younger cells!
Another important discovery was that this process did not occur instantaneously. Epigenetic rejuvenation continued over several weeks, even under experimental conditions that inhibited cell proliferation. This suggests that the loss of age-associated molecular signatures is not simply a consequence of rapidly multiplying cells replacing older ones. Instead, it appears to involve a prolonged process of cellular reorganisation.
The implications extend beyond the immediate objective of producing neural stem cells. Ageing involves changes in gene expression, DNA methylation, mitochondrial function, protein regulation and numerous other cellular processes. If some of these changes can be reversed experimentally, then at least certain molecular features of ageing are more plastic than previously assumed.
That is an important conceptual advance. It challenges the simplistic picture of biological ageing as an entirely irreversible accumulation of cellular deterioration.
However, there is a critical distinction between making a cell appear younger according to molecular measurements and actually restoring the health of an ageing human being. Epigenetic clocks are useful research instruments, but they are not direct measurements of remaining lifespan. A cell whose methylation pattern resembles that of a much younger cell has not necessarily recovered every youthful function, nor has it been demonstrated that such a cell would survive longer or perform better after transplantation.
The study was also conducted using cells manipulated under laboratory conditions. The researchers did not rejuvenate the bodies of elderly participants, reverse their neurological decline or demonstrate any extension of human lifespan. Indeed, the conversion process fundamentally changed the identity of the original cells, transforming blood-derived cells into neural stem cells. This is not the same thing as rejuvenating an ageing brain while preserving its existing neural networks, memories and functions.
For those interested in longevity, the most promising potential application may therefore lie in regenerative medicine. Ageing tissues often lose their capacity to repair damage, while stem cells themselves can become less effective with advancing age. If researchers can generate functionally youthful replacement cells from elderly patients, they may eventually be able to develop treatments for certain forms of tissue degeneration.
Neurological disorders are an especially interesting possibility. Parkinson's disease, for example, involves the progressive loss of particular populations of dopamine-producing neurons. The ability to generate suitable neural cells from a patient's own tissues could contribute to future cell-replacement strategies. Similar principles might eventually assist research into other degenerative conditions, although the technical and safety obstacles remain considerable.
There are also risks. Cellular reprogramming involves altering powerful regulatory mechanisms, and cMYC is associated with cancer biology. Any attempt to apply such techniques therapeutically would require careful control of cellular identity, genetic stability, abnormal proliferation and tumour formation. A treatment that produced younger-looking cells but increased cancer risk would hardly constitute a successful longevity intervention.
This raises a broader issue frequently overlooked in popular discussions of anti-ageing research. Living longer is not simply a matter of persuading individual cells to behave as though they were younger. The human organism is an extraordinarily complex system involving interactions between the nervous system, immune system, cardiovascular system, metabolism and countless other biological processes. Rejuvenating one cellular population does not automatically rejuvenate the entire organism.
There is also the distinction between lifespan and healthspan. Extending life while leaving people burdened by severe disability and degenerative disease would be a limited achievement. The more worthwhile objective is to extend the period during which individuals retain physical independence, cognitive abilities and reasonable quality of life.
What, then, should an ordinary person hoping to live longer take from this research? At present, there is no treatment arising from this particular study that can be purchased, prescribed or incorporated into a personal longevity programme. Nor does the research establish that supplements, dietary interventions or commercial epigenetic-age tests can reproduce its findings. The cellular changes were achieved through sophisticated laboratory reprogramming, not through an intervention that individuals can undertake themselves.
The practical measures with the strongest established evidence remain considerably less glamorous: avoiding tobacco, maintaining physical activity, controlling blood pressure, managing cardiovascular and metabolic risks, obtaining adequate sleep, and preserving muscle strength and mobility with advancing age.
Such measures may seem mundane compared with the prospect of turning a century-old cell into a biologically youthful one. Yet they are presently much more relevant to the individual hoping to remain healthy into their eighties, nineties or beyond.
The significance of the new research is therefore primarily scientific rather than immediately clinical. It strengthens the evidence that some molecular characteristics associated with ageing can be extensively remodelled, even in cells originating from exceptionally old individuals. It also offers researchers a useful experimental system for investigating how this rejuvenation occurs.
If future research can identify the mechanisms responsible, separate beneficial rejuvenation from potentially dangerous cellular changes, and reproduce meaningful improvements in living tissues, the consequences for regenerative medicine could be substantial.
For now, the study does not demonstrate that human ageing has been defeated, or that people will soon be living to 150. It does, however, add to the growing evidence that aspects of biological ageing are not necessarily fixed and irreversible.
That is a significant discovery in itself. The road from rejuvenating cells in a laboratory dish to extending healthy human life may be long, but understanding how old cells can acquire youthful molecular characteristics is one potentially important step along it.
Reference
Berg, L. J., Franzen, J., Buness, A., et al. (2026). Protracted fate acquisition and epigenetic de-aging during induced neural stem cell conversion of human blood cells. Aging Cell, 25(10), e70751. https://doi.org/10.1111/acel.70751